Corticosteroids: Still at the Frontline in Asthma Treatment?
Introduction
There was a time when asthmatics had their symptoms treated with a regular short-acting bronchodilator and theophylline, while reserving the use of systemic corticosteroids for severe exacerbations and for chronic maintenance treatment of the most severe patients. The emergence of corticosteroids suitable for the inhaled route in the 1970s followed by convincing clinical trials during the late 1980s has dramatically changed the picture of asthma treatment. The class of inhaled corticosteroids (ICS) has rapidly demonstrated its superiority over other classes of drugs used in asthma.1 The first Global Initiative for Asthma consensus in the early 1990s further highlighted the importance of the role of ICS in asthma treatment.2 There is no doubt that the reduced mortality and morbidity of asthma observed since the 1990s is, in a large part, related to the regular use of ICS as the mainstay of asthma treatment. Yet some studies have pointed out the variability of the response to ICS in patients with asthma, suggesting that ICS administered alone might not be the best drug for all patients.3
Section snippets
From early promise to the time of certitude
The first studies using inhaled hydrocortisone and prednisone in asthma were disappointing. It became apparent that this was because of the inappropriate chemical structure of prednisone, which has first to be metabolized to become pharmacologically effective, and the lack of topical activity of these corticosteroids. The chemical transformation of prednisone to increase both lipophilicity and interaction with glucocorticosteroid receptor made it possible to find compounds that were suitable
Corticosteroids and loss of lung function
Accelerated lung decline is a well-known feature of chronic obstructive pulmonary disease (COPD) and it is generally accepted that ICS fails to prevent it when patients continue to smoke.25 The recognition that patients with asthma also have an accelerated lung function decline regardless of smoking26, 27 and despite regular treatment with ICS24, 28 has questioned the role of this class of drugs as a disease-modifying agent in asthma. In contrast to what has been shown for airway inflammation,
The recognition of refractory asthma
The Gaining Optimal Asthma Control study showed that most patients with asthma can become largely asymptomatic when regularly treated by a combination ICS/LABA.35 This therapeutic strategy also proved to be efficient in preventing asthma exacerbation in most patients. Yet a small fraction of patients with asthma, called patients with refractory or severe asthma, escape to that treatment. Severe or refractory asthma is generally thought to affect 1% to 5% of all patients with asthma and accounts
The molecular concept of corticosteroid resistance
It has been well demonstrated that corticosteroids have a positive interaction with β2-agonists at the molecular level. Indeed, corticosteroids increase the transcription of the β2-agonist receptor, resulting in increased expression of the receptor at the cell surface.52, 53 On the other hand, there is growing evidence to show that β2-agonists enhance the action of corticosteroids, particularly through enhancing the translocation of glucocorticoid receptor (GR), therefore, increasing the
Complementary treatment to corticosteroids in refractory asthma
Although abundantly used in COPD, tiotropium has been poorly validated in asthma treatment. A recent study conducted in patients with uncontrolled asthma, despite a moderate dose of inhaled beclomethasone, showed that tiotropium was at least equivalent to salmeterol in improving asthma lung function and symptoms.65 Further studies focusing on patients with more severe asthma and looking at exacerbations as the major outcome are now warranted to validate the use of a long-acting anticholinergic
Emergence of the concept of asthma phenotype in mild to moderate asthma
The development of the technique of induced sputum has been a key step in the appearance of the concept of inflammatory phenotype in asthma. Although it confirmed the eosinophilic inflammation as a prominent feature of asthma,96 which relates to disease severity,43, 50, 72 it also showed that up to 50% of patients with asthma failed to exhibit this eosinophilic phenotype.97, 98 Almost half of them are characterized by intense neutrophilic inflammation99 but the other half fails to show any
Predicting factors of clinical response to corticosteroids
The results of large, randomized controlled clinical trials have perhaps masked for too long the fact that the response of ICS is variable in patients with asthma.105 As pointed out earlier, the response to ICS is characterized by a high intraindividual repeatability and a high interindividual variability, with up to 40% of patients showing no short-term response to the treatment.3 The presence of a persistent airway eosinophilic inflammation seems to be a good predicting factor for a
Corticosteroids in clinical practice
Like in many chronic diseases, poor compliance to maintenance treatment has been shown to be a major issue in asthma.117 Poor inhalation technique is a further impediment in achieving a successful treatment with inhaled therapies in patients with asthma.117 Because corticosteroids do not bring acute relief for asthma symptoms, it is likely to play a role in poor compliance. Although ICS have clearly demonstrated superior efficacy to leukotriene receptor antagonists with respect to most clinical
New class drug in development
There are several new drugs for asthma currently in development that may be suited more for patients who do not respond well to corticosteroids.91 Several cytokines are involved in the pathophysiology of asthma, including Th2 cytokines. Anti–IL-5 antibodies (mepolizumab, reslizumab) are currently in clinical trials for severe eosinophilic asthma that is resistant to corticosteroids, as discussed earlier. IL-13 is increased in severe asthma and causes corticosteroid resistance, so it is a
Summary
There is no doubt that ICS have led to considerably improved asthma control and reduced asthma mortality in the Western world over the last 2 decades. ICS are particularly effective in combating Th2-driven inflammation featuring mast-cell and eosinophilic airway infiltration. Their effect on innate immunity-driven neutrophilic inflammation is poor and their ability to prevent airway remodeling and accelerated lung decline is highly controversial. Although ICS remain pivotal drugs in asthma
Acknowledgments
The work was supported by federal grant PAI P7/30 Aireway II. We also thank Anne Chevremont for excellent technical assistance.
References (124)
- et al.
Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma
Lancet
(1973) - et al.
A short-term double-blind trial of aerosol triamcinolone acetonide in steroid-dependent patients with severe asthma
Chest
(1976) - et al.
A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial
J Allergy Clin Immunol
(1992) - et al.
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
Lancet
(2003) - et al.
Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma
Chest
(2006) - et al.
Histopathology of severe childhood asthma: a case series
Chest
(2003) - et al.
Severe asthma in adults: what are the important questions?
J Allergy Clin Immunol
(2007) - et al.
Chronic sinusitis in severe asthma is related to sputum eosinophilia
J Allergy Clin Immunol
(2002) - et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Lancet
(2002) - et al.
Glucocorticoid resistance in inflammatory diseases
Lancet
(2009)
Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling
Lancet
Reduced histone deacetylase in COPD: clinical implications
Chest
p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma
J Allergy Clin Immunol
Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients
J Allergy Clin Immunol
Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model
J Allergy Clin Immunol
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
Lancet
Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease
Cytokine
New therapies for asthma: is there any progress?
Trends Pharmacol Sci
Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8
Chest
Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease
Lancet
Will it be steroids for ever?
Clin Exp Allergy
Global strategy for asthma management and prevention: NHLBI/WHO workshop report March 1993
Heterogeneity of therapeutic responses in asthma
Br Med Bull
Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma
Br Med J
Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991
Med Care
Inhaled corticosteroids and the prevention of readmission to hospital for asthma
Am J Respir Crit Care Med
Low-dose inhaled corticosteroids and the prevention of death from asthma
N Engl J Med
Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
N Engl J Med
Mucosal inflammation in asthma
Am Rev Respir Dis
Allergy and allergic diseases. First of two parts
N Engl J Med
The eotaxins in asthma and allergic inflammation: implications for therapy
Curr Opin Investig Drugs
Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma
Am Rev Respir Dis
Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma
Am J Respir Crit Care Med
Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation
Eur Respir J
An inhaled steroid improves markers of airway inflammation in patients with mild asthma
Eur Respir J
Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma
Thorax
Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma
Thorax
CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy
Am Rev Respir Dis
Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids
J Clin Invest
Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease
PLoS Med
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease
N Engl J Med
Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking
Am J Respir Crit Care Med
15-year follow-up study of ventilatory function in adults with asthma
N Engl J Med
Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group
Am J Respir Crit Care Med
Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma
Thorax
Ultrastructural examination of bronchial biopsy specimens from children with moderate asthma
Thorax
Airway remodeling in asthma: new insights
J Allergy Clin Immunol
Effect of bronchoconstriction on airway remodeling in asthma
N Engl J Med
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study
Am J Respir Crit Care Med
Asthma severity and medical resource utilisation
Eur Respir J
Cited by (37)
Evidence for 2 clusters among patients with noneosinophilic asthma
2024, Annals of Allergy, Asthma and ImmunologyRevisiting differences between atopic and non-atopic asthmatics: When age is shaping airway inflammatory profile
2022, World Allergy Organization JournalCitation Excerpt :ICS treatment can modify asthma endotype and sputum cellularity. Indeed, inhaled corticosteroids (ICS) have demonstrated their ability to control airway inflammation by reducing eosinophilic airway infiltration.43 Previous studies showed that an initiation of ICS reduced sputum eosinophils.44–46
Pharmacological Management of Asthma and COPD
2022, Comprehensive PharmacologyAirways exudation of plasma macromolecules: Innate defense, epithelial regeneration, and asthma
2019, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Furthermore, as demonstrated in guinea pigs in vivo, plasma exudation and epithelial regeneration responses to airway epithelial denudation have been refractory to steroid treatment.162 This observation is of interest because steroid treatment is not known to prevent asthma development, and in patients with severe asthma, plasma exudation,117 along with central disease features, can also be refractory in part to steroid treatment effects.163,164 Airway plasma exudation not only reflects an active inflammatory process but also is a significant feature of epithelial regeneration, and it has a role in first-line innate defense.
Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying
2017, Journal of Pharmaceutical SciencesCitation Excerpt :Glucocorticosteroids are one of the most widely used drugs for asthma treatment.1,2
Longer duration of asthma is significantly associated with increased RV/TLC ratio
2017, Respiratory Medicine